11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage

Neurology

Volumn 74, Issue 6, 2010, Pages 487-493

  Ly, J V ^a   Donnan, G A ^a   Villemagne, V L ^b   Zavala, J A ^a   Ma, H ^a   O'Keefe, G ^b   Gong, S J ^b   Gunawan, R M ^a   Saunder, T ^b   Ackerman, U ^b   Tochon Danguy, H ^b   Churilov, L ^a   Phan, T G ^c   Rowe, C C ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

^c MONASH MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PITTSBURGH COMPOUND B C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; BENZOTHIAZOLE DERIVATIVE; CARBON; DIAGNOSTIC AGENT; N METHYL 2 (4' METHYLAMINOPHENYL) 6 HYDROXYBENZOTHIAZOLE; N-METHYL-2-(4'-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE;

ADULT; AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN HEMORRHAGE; BRAIN MAPPING; CEREBELLUM CORTEX; CEREBRAL AMYLOID ANGIOPATHY RELATED HEMORRHAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BINDING; DRUG DISTRIBUTION; DRUG UPTAKE; HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; VASCULAR AMYLOIDOSIS; BLEEDING; FEMALE; MALE; MENTAL HEALTH; METABOLISM; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSPECTIVE STUDY; QUESTIONNAIRE; RETROSPECTIVE STUDY; SCINTISCANNING;

AGED; AGED, 80 AND OVER; BENZOTHIAZOLES; CARBON RADIOISOTOPES; CEREBRAL AMYLOID ANGIOPATHY; FEMALE; HEMORRHAGE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; QUESTIONNAIRES; RETROSPECTIVE STUDIES;

EID: 76649142080     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181cef7e3     Document Type: Article

References (40)

1. Itoh Y, Yamada M. Cerebral amyloid angiopathy in the elderly: the clinicopathological features, pathogenesis, and risk factors. J Med Dent Sci 1997;44:11-19.
2. Greenberg SM, Briggs ME, Hyman BT, et al. Apolipopro-tein E epsilon 4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy. Stroke 1996;27:1333-1337.
3. Greenberg SM, Rebeck GW, Vonsattel JP, Gomez-Isla T, Hyman BT. Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol 1995;38:254-259.
4. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003;46:2740-2754.
5. Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006;129:2856-2866.
6. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004;55:306-319.
7. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007; 68:1718-1725.
8. Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007;62:229-234.
9. Greenberg SM, Eng JA, Ning M, Smith EE, Rosand J. Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage. Stroke 2004;35:1415-1420. (Pubitemid 38697468)
10. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
11. Jorm AF. The Informant Questionnaire on cognitive decline in the elderly (IQCODE): a review. Int Psychogeriatr 2004;16:275-293.
12. Browne J, de Pierro AB. A row-action alternative to the EM algorithm for maximizing likelihood in emission tomography. IEEE Trans Med Imaging 1996;15:687-699.
13. Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005; 46:1959-1972.
14. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J Cereb Blood Flow Metab 2005;25:1528-1547.
15. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996;16:834-840.
16. Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology 2001;56:537-539. (Pubitemid 32172884)
17. Rosand J, Muzikansky A, Kumar A, et al. Spatial clustering of hemorrhages in probable cerebral amyloid angiopathy. Ann Neurol 2005;58:459-462.
18. Koennecke HC. Cerebral microbleeds on MRI: prevalence, associations, and potential clinical implications. Neurology 2006;66:165-171.
19. Bacskai BJ, Frosch MP, Freeman SH, et al. Molecular imaging with Pittsburgh compound B confirmed at autopsy: a case report. Arch Neurol 2007;64:431-434.
20. Tomonaga M. Cerebral amyloid angiopathy in the elderly. J Am Geriatr Soc 1981;29:151-157.
21. Vinters HV, Gilbert JJ. Cerebral amyloid angiopathy: incidence and complications in the aging brain, II: the distribution of amyloid vascular changes. Stroke 1983;14:924-928.
22. Glenner GG, Henry JH, Fujihara S. Congophilic angiopathy in the pathogenesis of Alzheimer's degeneration. Ann Pathol 1981;1:120-129.
23. Itoh Y, Yamada M, Hayakawa M, Otomo E, Miyatake T. Subpial beta/A4 peptide deposits are closely associated with amyloid angiopathy in the elderly. Neurosci Lett 1993;155:144-147.
24. Vinters HV, Wang ZZ, Secor DL. Brain parenchymal and microvascular amyloid in Alzheimer's disease. Brain Pathol 1996;6:179-195.
25. Cosgrove GR, Leblanc R, Meagher-Villemure K, Ethier R. Cerebral amyloid angiopathy. Neurology 1985;35:625-631.
26. Vinters HV. Cerebral amyloid angiopathy: a critical review. Stroke 1987;18:311-324.
27. Yoshimura M, Yamanouchi H, Kuzuhara S, et al. Dementia in cerebral amyloid angiopathy: a clinicopathological study. J Neurol 1992;239:441-450.
28. Ellis RJ, Olichney JM, Thal LJ, et al. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, part XV. Neurology 1996;46:1592-1596.
29. Pettersen JA, Sathiyamoorthy G, Gao FQ, et al. Microb-leed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook Dementia Study. Arch Neurol 2008;65:790-795.
30. Jellinger KA, Attems J. Prevalence and pathogenic role of cerebrovascular lesions in Alzheimer disease. J Neurol Sci 2005;229-230:37-41.
31. Pfeifer LA, White LR, Ross GW, Petrovitch H, Launer LJ. Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology 2002;58:1629-1634.
32. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-259.
33. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 1997;28:2109-2118.
34. Kase CS, O'Neal AM, Fisher M, Girgis GN, Ordia JI. Intracra-nial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis. Ann Intern Med 1990;112:17-21.
35. Leblanc RHG, Robitaille Y. Cerebral hemorrhage from amyloid angiopathy and coronary thrombolysis. Neuro-surgery 1992;31:586-590.
36. McCarron MO, Nicoll JA. Cerebral amyloid angiopathy and thrombolysis-related intracerebral haemorrhage. Lancet Neurol 2004;3:484-492.
37. Pendlebury WW, Iole ED, Tracy RP, Dill BA. Intracere-bral hemorrhage related to cerebral amyloid angiopathy and t-PA treatment. Ann Intern Med 1991;29:210-213.
38. Ramsay DA, Penswick JL, Robertson DM. Fatal streptokinase-induced intracerebral haemorrhage in cerebral amyloid angiopathy. Can J Neurol Sci 1990;17:336-341.
39. Gervais F, Chalifour R, Garceau D, et al. Glycosaminogly-can mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid 2001;8(suppl 1):28-35.
40. Greenberg SM, Rosand J, Schneider AT, et al. A phase 2 study of tramiprosate for cerebral amyloid angiopathy. Alzheimer Dis Assoc Disord 2006;20:269-274.